TriSalus Life Sciences (TLSI) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
TriSalus Life Sciences Announces Preliminary Q4 and Full Year Unaudited 2024 Financial Results and Conference Call
January 23, 2025 8:00 AM ESTQ4 Revenue of approximately $8.3 million represents approximately 44% growth versus Q4 2023 Full year 2024 Revenue of approximately $29.4 million represent approximately 59% growth versus full year 2023 Q4 Operating Cash Flow of approximately ($5.6) million is a notable improvement compared to ($10.8) million in Q3 Company expects to achieve positive full year EBITDA in 2025 and positive Cash Flow during the second half of 2025
Call Scheduled for Thursday, March 27, 2025, at 8:00 a.m. ET
DENVER--(BUSINESS... More
